DEXAMETHASONE SODIUM PHOSPHATE INJECTION, USP SOLUTION

País: Canadá

Língua: inglês

Origem: Health Canada

Ingredientes ativos:

DEXAMETHASONE PHOSPHATE (DEXAMETHASONE SODIUM PHOSPHATE)

Disponível em:

STRIDES PHARMA CANADA INC

Código ATC:

H02AB02

DCI (Denominação Comum Internacional):

DEXAMETHASONE

Dosagem:

4MG

Forma farmacêutica:

SOLUTION

Composição:

DEXAMETHASONE PHOSPHATE (DEXAMETHASONE SODIUM PHOSPHATE) 4MG

Via de administração:

INTRAVENOUS

Unidades em pacote:

5ML

Tipo de prescrição:

Prescription

Área terapêutica:

ADRENALS

Resumo do produto:

Active ingredient group (AIG) number: 0106305003; AHFS:

Status de autorização:

APPROVED

Data de autorização:

2020-07-30

Características técnicas

1
PRESCRIBING INFORMATION
PR
DEXAMETHASONE SODIUM PHOSPHATE INJECTION, USP
4 MG/ML
STERILE SOLUTION FOR INTRAVENOUS, INTRAMUSCULAR, INTRA-ARTICULAR,
INTRALESIONAL, AND
SOFT TISSUE INJECTION
10 MG/ML STERILE SOLUTION FOR INTRAVENOUS, INTRAMUSCULAR
CORTICOSTEROID
Strides Pharma Canada Inc.
Date of revision
1565, Boul. Lionel-Boulet
July 30, 2020
Varennes, Quebec
J3X 1P7
Submission Control No.: 240776
2
PR
DEXAMETHASONE SODIUM PHOSPHATE INJECTION, USP
4 MG/ML
STERILE SOLUTION FOR INTRAVENOUS, INTRAMUSCULAR, INTRA-ARTICULAR,
INTRALESIONAL, AND
SOFT TISSUE INJECTION
10 MG/ML STERILE SOLUTION FOR INTRAVENOUS, INTRAMUSCULAR
CORTICOSTEROID
INDICATIONS
Dexamethasone Sodium Phosphate Injection may be given by I.V. or I.M.
injection when oral
therapy is not feasible in the following conditions:
ENDOCRINE DISORDERS: Primary or secondary adrenocortical insufficiency
(hydrocortisone or
cortisone
is
the
drug
of
choice;
synthetic
analogs
may
be
used
in
conjunction
with
mineralocorticoid
where
applicable;
in
infancy,
mineralocorticoid
supplementation
is
of
particular importance). Acute adrenocortical insufficiency
(hydrocortisone or cortisone is the
drug of choice; mineralocorticoid supplementation may be necessary,
particularly when synthetic
analogs are used). Preoperatively and in the event of serious trauma
or illness, in patients with
known adrenal insufficiency or when adrenocortical reserve is
doubtful.
Congenital adrenal hyperplasia.
Nonsupportive thyroiditis.
SHOCK: The adjunctive treatment of shock where high (pharmacologic)
doses of corticosteroids
are needed: e.g., severe shock of hemorrhagic, traumatic, surgical, or
septic origin. Treatment
with Dexamethasone Sodium Phosphate Injection is an adjunct to, and
not a substitute for,
specific or supportive measures that the patient may require, e.g.,
restoration of circulating blood
volume, correction of fluid and electrolyte balance, oxygen, surgical
measures and antibiotics.
RHEUMATIC DISORDERS: As adjunctive therapy for short-term
administration (to support the
patient